<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02518568</url>
  </required_header>
  <id_info>
    <org_study_id>V00355 CP 1 02</org_study_id>
    <secondary_id>2015-000544-42</secondary_id>
    <nct_id>NCT02518568</nct_id>
  </id_info>
  <brief_title>Ferrous Sulphate Supplement (V0355) in Women With Iron Deficiency Anaemia</brief_title>
  <official_title>Study of the Pharmacokinetics of Serum Iron After a Single Oral Administration of Ferrous Sulphate Supplement Synthetic Formula in Women With Iron Deficiency Anaemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the pharmacokinetics of serum iron after a single&#xD;
      oral administration of 160 mg (2 tablets of 80 mg) V0355 in women with iron deficiency&#xD;
      anaemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma concentration (Cmax)</measure>
    <time_frame>up to 24 hours after oral administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Concentration (Tmax)</measure>
    <time_frame>up to 24 hours after oral administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the iron plasma concentration curve (AUC)</measure>
    <time_frame>up to 24 hours after oral administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of single administration</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Tolerability by evaluating the number of subjects with emergent adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V0355</intervention_name>
    <description>Oral administration (2 tablets)</description>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women 18-45 years inclusive with iron deficiency anaemia&#xD;
&#xD;
          -  haemoglobin level between 85 g/L and 105 g/L&#xD;
&#xD;
          -  serum ferritin level &lt; 15 Âµg/L&#xD;
&#xD;
          -  D14 +/- 7 days of the menstruation cycle on the day of pharmacokinetic evaluation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anaemia related to other causes than iron deficiency and particularly inflammatory&#xD;
             anaemia, anaemia due to marrow failure, haemopathy, haemoglobinopathies (sickle cell&#xD;
             disease, thalassemia), haemolytic anaemia, anaemia due to acute haemorrhage, or&#xD;
             anaemia related to chronic renal failure,&#xD;
&#xD;
          -  Haemochromatosis or iron overload of secondary origin (blood transfusion),&#xD;
&#xD;
          -  Long term treatment known to modify iron absorption,&#xD;
&#xD;
          -  Gastro duodenal ulcer,&#xD;
&#xD;
          -  Inflammatory bowel disease or any digestive disease which could modify iron&#xD;
             absorption,&#xD;
&#xD;
          -  Serious or progressive disease (cardiac, pulmonary, hepatic, renal, haematological,&#xD;
             malignancy, autoimmune disease, infectious disease or neuropsychiatric disorders),&#xD;
&#xD;
          -  Surgery undergone within 1 month prior to selection visit or a surgery planned during&#xD;
             the study realization.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

